CONGRESS ABSTRACT

Background: The aim of the present study was to evaluate the profile of patients prescribed Bempedoic acid (BA) in outpatient clinical practice in the Campania Region; in addition, the efficacy, tolerability of the drug and therapeutic adherence in short-term follow-up were assessed. Methods: The BeACON (Bempedoic Acid in Campania: optimizing need) study is a prospective observational registry that included all patients from 6 hospital outpatient clinics in the Campania Region who were prescribed BA between 15 September 2023 – 15 December 2023 and followed up for at least 6 months. All patients underwent lipid profile, uric acid and CPK dosage at study inclusion and at 6 months after the start of therapy. Renal and hepatic function was also assessed. The efficacy of the drug was assessed by the reduction in LDL-cholesterol compared to baseline. Safety of the drug was assessed by reported adverse events. Results: Data from 111 patients (65.6± 9.6 years; 38.7% women) who were prescribed bempedoic acid alone (n: 68; 61.3%) or in fixed combination with ezetimibe (n: 43; 38.7%) were analysed. The clinical characteristics of the study population are presented in Table 1. 98 patients (88%) had a very high cardiovascular risk profile, 13 patients (22%) had a high risk profile. Only 1 patient in each group had target LDL per risk category. In 30 patients (27%) AB was prescribed instead of statins due to reported intolerance.  In 63 patients (57%) BA was prescribed instead in addition to maximum tolerated statin therapy. In particular in 56 patients (50.4%) BA was added to the fixed statin/ezetimibe combination; in 6 patients (5.4%) in addition to triple therapy with statin/ezetimibe and PCSK9 inhibitors; in 9 patients (8.1%) in addition to PCSK9 inhibitors alone. At the first follow-up after a median time of 44 days of therapy, 41.4 % of the patients reached the therapeutic target, in particular 47 % in the very high risk group and 15 % in the high risk group. Three patients (2.7%) discontinued BA due to reported intolerance to the drug. Conclusion: Preliminary analysis of the BeACON registry showed that bempedoic acid, alone or in fixed combination with ezetimibe, was prescribed in 57% of the cases in addition to maximum tolerated therapy with statins and other hypolipidemic agents to patients at high or very high risk and only in 27% to patients intolerant to statins. With the addition of bempedoic acid 1 in 2 patients reached the therapeutic target.